Efficacy News and Research

RSS

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

Evaluating stroke-prevention strategies in patients with atrial fibrillation by age

The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide.

20 May 2026

ChatCPR instructor delivers near-perfect CPR guidance in proof-of-concept study

A proof-of-concept JAMA Internal Medicine study found that widely available AI models could deliver many guideline-concordant CPR instructions in simulated out-of-hospital cardiac arrest scenarios. A purpose-built AI agent, ChatCPR, achieved higher checklist-based adherence than baseline AI models and dispatcher-assisted CPR instructions, but prospective real-world validation is still needed.

20 May 2026

Wastewater tracking catches hospital fungus before patients show symptoms

A new UNLV-led wastewater surveillance study brings scientists one step closer in the global race to detect and deter skyrocketing cases of a potentially deadly drug-resistant fungus that puts hospital patients at risk of serious blood, heart, or brain infections.

20 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Rerouting dead tumor debris enhances cancer immunotherapy outcomes

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

20 May 2026

Ensitrelvir cuts household COVID-19 risk when given after exposure

Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.0% of placebo recipients, with similar overall adverse-event rates.

20 May 2026

Biomimetic nanocomposite hydrogel promotes tendon healing and tissue regeneration

The new system, termed KGN@PB@CM, combines several advanced elements. Prussian blue (PB) nanozymes act as potent reactive oxygen species (ROS) scavengers, while kartogenin (KGN)-a small molecule that promotes stem cell migration and tenogenic differentiation-is loaded onto the PB core.

20 May 2026

Methylene blue enhances hair follicle stem cell regeneration under stress

A new research paper was published in Volume 18 of Aging-US on May 5, 2026, titled "Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration."

19 May 2026

Study supports flexible blood transfusion options in emergency trauma care

Giving whole blood or the component parts of blood are equally effective options for paramedics and emergency medical technicians to use in treating patients with severe, traumatic bleeding before arriving at the hospital, according to a large, nationwide trial directed by University of Pittsburgh and UPMC clinicians and scientists.

19 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Tezepelumab reduces asthma exacerbations in diverse patient population

The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials.

18 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

How Andes virus super-spreaders reveal the risk behind the MV Hondius hantavirus cluster

A 2020 NEJM study of the 2018 to 2019 Epuyén outbreak showed that Andes virus spread from one zoonotic introduction into four generations of human infection, causing 34 cases and 11 deaths. The findings are newly relevant after WHO reported an ANDV cluster linked to the MV Hondius cruise ship, where close indoor exposure may have enabled onboard human-to-human transmission.

14 May 2026

Thyroid hormone profiles provide critical prognostic clues for patients facing liver failure

Early and accurate prognostic assessment is crucial to prevent disease progression in liver failure. Thyroid hormones (THs), particularly triiodothyronine (T3), are key metabolic regulators and play an important role in liver regeneration. Liver failure is frequently complicated by non‑thyroidal illness syndrome (NTIS), characterized by low T3 with normal or slightly elevated TSH and T4.

14 May 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

Sequential TACE after SBRT improves outcomes in recurrent hepatocellular carcinoma

Comparative data on sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) in recurrent hepatocellular carcinoma (HCC) remain limited. This study aimed to evaluate the efficacy of this combination.

13 May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026